drugset
drugset / Trial / NCT07586514

A Study to Assess Safety, Tolerability and Exposure of 4ET1103 in Healthy Human Volunteers

NCT07586514 ↗

Phase 1 Completed 40 enrolled 4E Therapeutics National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will dose healthy human volunteers with either active drug (4ET1103) or placebo. Each study subject will receive a single dose of either active drug or placebo, and will then be monitored for safety, tolerability and exposure of active drug.

Timeline

Start
2025-04-18
Primary completion
2025-08-18
Completion
2025-08-18

Drugs

EvaluationDrugModalityDoseRoute
Subject 4ET1103 Unknown 45 mg Oral
Subject 4ET1103 Unknown 135 mg Oral
Subject 4ET1103 Unknown 270 mg Oral
Subject 4ET1103 Unknown 450 mg Oral
Subject 4ET1103 Unknown 720 mg Oral

Indications

neuropathy, painful